Our major challenge will be to provide tools that can help in precise selection of these patients. The challenge will not only be restricted to an accurate evaluation Fusion imaging is not new. However when combined with volume imaging and navigation, it becomes a very strong tool broadening ultrasound as well as CT clinical applications for both diagnostic and interventional practices and in particular in guiding therapy without or reduced ionising radiation. Currently available systems have been shown to be useful in a) the US tracking of liver and renal lesions for detection, characterisation of difficult/occult lesions and follow-up following therapy, b) in the guidance of biopsy and ablation of occult liver or renal tumours as well as c) a much needed training tool for interventional clinicians. A practical work-flow through various fusion and navigation systems for the clinical applications as well as their current benefits, limitations and future developments will be reviewed. Preoperative staging of rectal cancer implies detailed recognition of tumour extent, providing the basis for multidisciplinary team (MDT) treatment planning. The role of diagnostic imaging continues to increase in this setting. There are technological advances in all imaging modalities, and treatment is based on a synthesis of information in each patient. Diagnostic imaging discussed in MDT conferences is recognised as a quality assurance parameter in rectal cancer, ensuring that the available prognostic information is adequately used all the way to treatment decision. The multidisciplinary approach also has continuous educational advantages. For radiologists, recognition and reporting of tumour relation to anatomical structures such as the mesorectal fascia, the peritoneal reflection, the levators and anal sphincters, as well as identification of extramural venous invasion, lymph node involvement and evaluation of tumour response to neoadjuvant treatment, are all important parts of this educational process. MDT-based imaging discussions continue to result in new surgical and oncological treatment strategies to be considered both in randomised clinical trials or in single patients. Being able to stratify patients into prognostic groups based on imaging may help to identify not only those in whom neoadjuvant treatment is beneficial, but also those where primary surgery can be performed without need for radio-or chemotherapy. In this session, the present role of different imaging techniques for local and distant staging of rectal cancer will be presented, including their advantages and limitations. New treatment strategies and challenges based on assessment of response to treatment will also be presented and discussed. Coronary computed tomography angiography (CCTA) using 64-detector rows or greater has been recently introduced as a novel non-invasive anatomic method for evaluation of CAD, demonstrating high diagnostic accuracy for detection and exclusion of obstructive CAD. Several recent reports have also examined the prognostic value of CCTA findings for prediction of future adverse CAD events, but have been generally limited to single centres and by small patient cohorts. Further, prior studies examining risk stratification by CCTA findings have been primarily restricted to measures of obstructive CAD by maximal luminal diameter stenosis severity on a per-patient or per-vessel basis, with other plaque characteristics visualised by CCTA, including location, distribution, extent, and composition and non-coronary cardiac findings including left ventricular systolic function, volume, and regional wall motion, largely neglected within development of prognostic models. Several preliminary studies showed that CCTA has an incremental value over traditional risk factors, coronary calcium score and other imaging tests for the prediction of cardiovascular events. The interesting value of CCTA is also related to the capability of stratification in the area of sub-clinical atherosclerosis and in the definition of plaque type. With the implementation of low-dose CCTA the prognostic potential of CCTA can be imagined as a reliable clinical information. At the moment there is one large international multicentre registry that started to explore the predictive potential of CCTA in large number of patients (> 20.000). Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the industrialised countries. In order to determine which patients are at risk to develop sudden cardiac death or non-fatal future cardiac events (e.g. myocardial infarction/ischaemia-related cardiac arrhythmias), traditional risk factors have been established. These are helpful to triage patients in high/intermediate/low risk groups. However, many patients in the high-risk group will never experience a cardiac event, while patients in the other risk groups can be falsely reassured. This has urged clinicians and scientists to assess novel prognostic factors better predicting future cardiac events. MRI, amongst other techniques, seems promising to improve prediction of patient prognosis. MRI is the reference technique to assess cardiac volumes and function. It allows to reliably assess the impact of coronary artery stenoses on myocardial perfusion and function in resting and stressed conditions, and this technique enables to noninvasively depict myocardial necrosis/ fibrosis and to fully characterise the jeopardised myocardium in the acute setting. These applications are not only useful in the diagnosis but also to predict clinical outcome and to assess patient prognosis as increasingly shown in literature. In this presentation, the added value of MRI in the different CAD subgroups (stable CAD, acute ischemic event, chronic ischemic cardiomyopathy) will be discussed in detail.